Unknown PHASE4 INTERVENTIONAL 2-arm NCT02625155

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens (SPHERE)

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE

Sponsor: InSource Diagnostics

Conditions Target Drug-related Adverse Events

Interventions Urine diagnostic testing as SOC, drug regimen changes per SOC Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results

Updated 6 times since 2017 Last updated: Feb 27, 2018 Started: Dec 31, 2015 Primary completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02625155, this PHASE4 trial focuses on Target Drug-related Adverse Events and remains ongoing. Sponsored by InSource Diagnostics, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Apr 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InSource Diagnostics
Syntactx

Data source: InSource Diagnostics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tazewell, United States